Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Dose Ranging Study of Dysport (AbobotulinumtoxinA) in the Treatment of Oromandibular Dystonia

Trial Profile

A Pilot Dose Ranging Study of Dysport (AbobotulinumtoxinA) in the Treatment of Oromandibular Dystonia

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Dystonia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 28 Apr 2017 Results assessing the efficacy and safety of botulinum toxin A [Dysport, abobotulinumtoxinA] in patients with oromandibular dystonia, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top